Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DR-0201 |
| Synonyms | |
| Therapy Description |
DR-0201 is a bispecific antibody targeting CD20, which potentially induces phagocytosis tumor cells expressing CD20 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DR-0201 | DR 0201|DR0201|SAR448501 | CD20 Antibody 26 | DR-0201 is a bispecific antibody targeting CD20, which potentially induces phagocytosis tumor cells expressing CD20 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06392477 | Phase I | DR-0201 | A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | AUS | 5 |